Ruben A. Mesa, MD, discusses research surrounding the upfront use of JAK2-targeted therapy, triggers of progression, and complementary approaches and novel agents that are currently under investigation.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
![Python - Полный Курс по Python [15 ЧАСОВ]](https://s2.save4k.su/pic/cfJrtx-k96U/mqdefault.jpg)
